Novel study is investigating dysregulation of the complement system during standard hemodialysis therapy in relation to patient health outcomes. GLASGOW, Scotland, June 13, 2023 /PRNewswire/ — Invizius Limited (“Invizius”), a biotechnology company developing second generation therapies…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.